SUBSCRIBERS
Hyphens Pharma International eyes Catalist listing
IPO will comprise a cornerstone offering as well as a placement and a public offering
Add BT as a preferred source
Nisha Ramchandani
Published Thu, Apr 26, 2018 · 09:50 PM
Singapore
HYPHENS Pharma International is seeking a listing on the Catalist board of the Singapore Exchange, with part of the proceeds from the inital public offering (IPO) to go towards expansion.
The pharmaceutical and consumer healthcare group's core business segments include speciality pharmaceutical products, proprietary brands such as Ceradan and Ocean Health supplements, as well as a wholesale medical hypermart and digital business.
Copyright SPH Media. All rights reserved.
